What this pack is
STALEVO is the brand name in this record; carbidopa, levodopa and entacapone is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
STALEVOGeneric namecarbidopa, levodopa and entacapone
How this medicine works
The current U.S. label explains that levodopa crosses the blood-brain barrier and is converted to dopamine in the brain; carbidopa inhibits peripheral levodopa decarboxylation, allowing more levodopa to reach the brain; and entacapone is a reversible, selective COMT inhibitor that affects another peripheral levodopa pathway. This mechanism explains why one tablet has three ingredients but cannot determine an individual's strength, frequency, switch or combination.
Read source: United States ↗Current regulatory record · reviewed 2026-08-27More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- STALEVO
- Generic name
- carbidopa, levodopa and entacapone
- Dosage-form class
- STALEVO fixed three-ingredient film-coated oral tablets: six named strengths, 50, 75, 100, 125, 150 and 200; every tablet contains carbidopa and levodopa plus a fixed 200 mg of entacapone; all are listed as 100-tablet bottles in the U.S. label
- Route
- Oral (higher-risk fixed three-ingredient product-identity field)
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
6 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (SPL v8, effective 27 Mar 2026; package panel marked Rev. 06/2021)
STALEVO 50: carbidopa 12.5 mg / levodopa 50 mg / entacapone 200 mg per tablet; 100-tablet bottle
- Product code
- NDC 52427-805-01
- Form and route
- STALEVO carbidopa/levodopa/entacapone film-coated oral tablet · oral (fixed three-ingredient product-identity field)
- Container
- HDPE bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-27; actual marketing, stock and availability are not established.
- carbidopa
- 12.5 mgfirst labelled ingredient per tablet; not an individual dose or conversion instruction
- levodopa
- 50 mgsecond labelled ingredient per tablet; not an individual dose or conversion instruction
- entacapone
- 200 mgthird labelled ingredient per tablet; all six strengths contain 200 mg, so multiple tablets or tablet portions must not be self-combined
- Package
- 100 tablets per bottle
- Labelled appearance
- brownish-red or greyish-red · round, biconvex, unscored film-coated tablet · imprint LCE 50Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v8, effective 27 Mar 2026; package panel marked Rev. 06/2021)
STALEVO 75: carbidopa 18.75 mg / levodopa 75 mg / entacapone 200 mg per tablet; 100-tablet bottle
- Product code
- NDC 52427-809-01
- Form and route
- STALEVO carbidopa/levodopa/entacapone film-coated oral tablet · oral (fixed three-ingredient product-identity field)
- Container
- HDPE bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-27; actual marketing, stock and availability are not established.
- carbidopa
- 18.75 mgfirst labelled ingredient per tablet; not an individual dose or conversion instruction
- levodopa
- 75 mgsecond labelled ingredient per tablet; not an individual dose or conversion instruction
- entacapone
- 200 mgthird labelled ingredient per tablet; all six strengths contain 200 mg, so multiple tablets or tablet portions must not be self-combined
- Package
- 100 tablets per bottle
- Labelled appearance
- light brownish-red · oval, unscored film-coated tablet · imprint LCE 75Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v8, effective 27 Mar 2026; package panel marked Rev. 06/2021)
STALEVO 100: carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg per tablet; 100-tablet bottle
- Product code
- NDC 52427-816-01
- Form and route
- STALEVO carbidopa/levodopa/entacapone film-coated oral tablet · oral (fixed three-ingredient product-identity field)
- Container
- HDPE bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-27; actual marketing, stock and availability are not established.
- carbidopa
- 25 mgfirst labelled ingredient per tablet; not an individual dose or conversion instruction
- levodopa
- 100 mgsecond labelled ingredient per tablet; not an individual dose or conversion instruction
- entacapone
- 200 mgthird labelled ingredient per tablet; all six strengths contain 200 mg, so multiple tablets or tablet portions must not be self-combined
- Package
- 100 tablets per bottle
- Labelled appearance
- brownish-red or greyish-red · oval, unscored film-coated tablet · imprint LCE 100Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v8, effective 27 Mar 2026; package panel marked Rev. 06/2021)
STALEVO 125: carbidopa 31.25 mg / levodopa 125 mg / entacapone 200 mg per tablet; 100-tablet bottle
- Product code
- NDC 52427-827-01
- Form and route
- STALEVO carbidopa/levodopa/entacapone film-coated oral tablet · oral (fixed three-ingredient product-identity field)
- Container
- HDPE bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-27; actual marketing, stock and availability are not established.
- carbidopa
- 31.25 mgfirst labelled ingredient per tablet; not an individual dose or conversion instruction
- levodopa
- 125 mgsecond labelled ingredient per tablet; not an individual dose or conversion instruction
- entacapone
- 200 mgthird labelled ingredient per tablet; all six strengths contain 200 mg, so multiple tablets or tablet portions must not be self-combined
- Package
- 100 tablets per bottle
- Labelled appearance
- light brownish-red · oval, unscored film-coated tablet · imprint LCE 125Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v8, effective 27 Mar 2026; package panel marked Rev. 06/2021)
STALEVO 150: carbidopa 37.5 mg / levodopa 150 mg / entacapone 200 mg per tablet; 100-tablet bottle
- Product code
- NDC 52427-834-01
- Form and route
- STALEVO carbidopa/levodopa/entacapone film-coated oral tablet · oral (fixed three-ingredient product-identity field)
- Container
- HDPE bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-27; actual marketing, stock and availability are not established.
- carbidopa
- 37.5 mgfirst labelled ingredient per tablet; not an individual dose or conversion instruction
- levodopa
- 150 mgsecond labelled ingredient per tablet; not an individual dose or conversion instruction
- entacapone
- 200 mgthird labelled ingredient per tablet; all six strengths contain 200 mg, so multiple tablets or tablet portions must not be self-combined
- Package
- 100 tablets per bottle
- Labelled appearance
- brownish-red or greyish-red · elongated oval, unscored film-coated tablet · imprint LCE 150Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v8, effective 27 Mar 2026; package panel marked Rev. 06/2021)
STALEVO 200: carbidopa 50 mg / levodopa 200 mg / entacapone 200 mg per tablet; 100-tablet bottle
- Product code
- NDC 52427-842-01
- Form and route
- STALEVO carbidopa/levodopa/entacapone film-coated oral tablet · oral (fixed three-ingredient product-identity field)
- Container
- HDPE bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-27; actual marketing, stock and availability are not established.
- carbidopa
- 50 mgfirst labelled ingredient per tablet; not an individual dose or conversion instruction
- levodopa
- 200 mgsecond labelled ingredient per tablet; not an individual dose or conversion instruction
- entacapone
- 200 mgthird labelled ingredient per tablet; all six strengths contain 200 mg, so multiple tablets or tablet portions must not be self-combined
- Package
- 100 tablets per bottle
- Labelled appearance
- dark brownish-red · oval, unscored film-coated tablet · imprint LCE 200Unscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
STALEVO label reading: three numbers belong to one tablet, and every strength contains entacapone 200 mg
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
STALEVO is a fixed three-ingredient combination, not a levodopa-only tablet. The current U.S. label says tablets must not be split, crushed or chewed and only one tablet is administered at each dosing interval. Every strength contains entacapone 200 mg; combining tablets or tablet portions to obtain more levodopa may cause entacapone overdose. The site does not turn this into an individual tablet count, schedule or conversion.
- Check STALEVO, all three ingredients, all three milligram amounts per tablet, NDC, 100-tablet bottle, LCE imprint and market together. The '100' in STALEVO 100 names the levodopa component only; the same tablet also contains carbidopa 25 mg and entacapone 200 mg.
- Do not treat STALEVO as another SINEMET pack. Both may name carbidopa/levodopa, but STALEVO also contains entacapone. Shared ingredients, nearby numbers or a similar purpose do not establish self-co-use, alternation, substitution or stacking. Have a pharmacist or prescriber review both actual packs and the complete medicine list.
- The current label also addresses hyperpyrexia and confusion after abrupt reduction or withdrawal, falling asleep during daily activities, orthostatic hypotension, dyskinesia, hallucinations, impulse-control problems, diarrhoea and interactions including warfarin. The site only prompts review of symptoms, falls, sleepiness and the complete medicine list; it does not provide self-stopping, reduction, make-up or spacing instructions.
- For loss of consciousness, a serious fall, breathing difficulty, marked confusion, high fever, suspected overdose or another acute serious concern, use local emergency or poison-information services immediately and bring all medicine packs; do not wait for a web search or try to counteract it with another Parkinson medicine.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-27
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. STALEVO public label (Almatica; SPL v8, effective 27 Mar 2026) ↗Current regulatory record · reviewed 2026-08-27
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-27FDA: STALEVO NDA 021485 administrative record and original-application approval date (11 Jun 2003) ↗Historical public record · reviewed 2026-08-27
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about STALEVO (carbidopa, levodopa and entacapone). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
STALEVO is the brand in this record and carbidopa, levodopa and entacapone is the active-ingredient name. Check both with the dosage form (STALEVO fixed three-ingredient film-coated oral tablets: six named strengths, 50, 75, 100, 125, 150 and 200; every tablet contains carbidopa and levodopa plus a fixed 200 mg of entacapone; all are listed as 100-tablet bottles in the U.S. label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. STALEVO public label (Almatica; SPL v8, effective 27 Mar 2026) ↗Current regulatory record · reviewed 2026-08-27
- FDA: STALEVO NDA 021485 administrative record and original-application approval date (11 Jun 2003) ↗Historical public record · reviewed 2026-08-27
HOW IT WORKS · NOT A TREATMENT PLAN
How the three ingredients work together: levodopa reaches the brain while peripheral decarboxylase and COMT pathways are inhibited
- Three pathways do not make the three milligram values separately calculable and do not create a web-computable equivalence between STALEVO and separate carbidopa/levodopa, entacapone or another Parkinson medicine.
- The label describes entacapone as a COMT inhibitor and states that every strength contains 200 mg. This constant amount is a key fixed-combination identity clue and one reason multiple tablets or tablet portions must not be self-combined to obtain more levodopa.
- A mechanism cannot explain the individual cause of sudden sleepiness, dizziness, hallucinations, diarrhoea, urine-colour change or symptom fluctuation. Record the timing and take the exact pack and complete medicine list for professional review; use urgent services first if severe or rapidly worsening.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. STALEVO public label (Almatica; SPL v8, effective 27 Mar 2026) ↗Current regulatory record · reviewed 2026-08-27
- FDA: STALEVO NDA 021485 administrative record and original-application approval date (11 Jun 2003) ↗Historical public record · reviewed 2026-08-27
SOURCE-TRACEABLE ARCHIVE
STALEVOcarbidopa, levodopa and entacapone
This page includes an exact current U.S. public-label package panel for STALEVO, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA NDA 021485 original application approval
The FDA administrative record links STALEVO, NDA 021485, an original NDA and the approval date 11 Jun 2003, initially covering STALEVO 50, 100 and 150. This U.S. node does not automatically establish another market's trade name, approval, supply, reference status or interchangeability.
FDA: STALEVO NDA 021485 administrative record and original-application approval date (11 Jun 2003) ↗Current DailyMed SPL v8 effective
The current U.S. public label lists six STALEVO strengths, six 100-tablet bottle NDCs, the whole-tablet boundary and the three-ingredient mechanism. The package panels themselves are marked Rev. 06/2021; the label effective date and package-panel version remain separate on this page.
DailyMed (NLM): current U.S. STALEVO public label (SPL v8, effective 27 Mar 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current NDA brand label, six exact three-ingredient strengths and six package panels linkedThis page separately records all three per-tablet ingredient amounts, NDC, 100-tablet bottle, LCE imprint and source for STALEVO 50, 75, 100, 125, 150 and 200. It supports product identity and safety reading; it does not authenticate a product or establish current stock, purchase, individual tablet count, interval, conversion, stopping or co-use.
Mainland China, the EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, reference/originator relationship or interchangeability is inferred from the U.S. NDA, DailyMed name, NDC, three milligram values, LCE imprint or package image; every market requires separate review against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Can I read only the middle 100 in STALEVO 100's 25/100/200?
No. 25/100/200 together identify carbidopa, levodopa and entacapone in the same tablet. The '100' in the name identifies only the levodopa component; the site does not split the three numbers into an individual dose or conversion formula.
Can STALEVO be split, or can two lower-strength tablets be combined to make a higher strength?
Do not do this from a webpage. The current U.S. label says not to split, crush or chew and states that every strength contains entacapone 200 mg; combining tablets or tablet portions to obtain more levodopa may cause entacapone overdose. Have a pharmacist or prescriber review the actual pack, prescription and complete medicine list.
If SINEMET is already on the list, can STALEVO be taken with it or alternated?
A webpage cannot decide this. Both may contain carbidopa/levodopa, while STALEVO additionally contains entacapone; shared ingredients create duplicate-ingredient and conversion risks. Have a pharmacist or prescriber review both actual products, the prescribed schedule and complete medicine list; do not self-stack, alternate, substitute or stop.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.